curasan AG appoints New Medical Director

Kleinostheim, Germany; Research Triangle Park, North Carolina, USA July 2016 – As of July 1, 2016 Dr. Gregor Thomas has been appointed as new Medical Director at curasan AG.

Dr. Thomas follows Dr. Wolf-Dietrich Hübner who will retire at the end of this year. Dr. Hübner has successfully managed his department in the leading position as a Medical Director over 12 years and has built up a competent team within this time. In the future Dr. Hübner will continue to lend his support to curasan as an advisor.

Dr. Thomas is an experienced executive who has held previous posts as a medical practitioner in leading industries focusing on clinical research and product development. In addition, Dr. Thomas brings valuable skills gained during his longtime experience as both orthopedic, oral surgeon and reconstructive dentistry specialties.

“Currently curasan is servicing two separate regenerative medicine fields – orthopaedics and dentistry. With Dr. Thomas we will benefit from his orthopedic and dental involvement and utilize his experiences to further both segments of our business worldwide.” Michael Schlenk, CEO of curasan AG, comments with pleasure. “Dr. Thomas earned his Ph.D in hip arthroplasty and therefore has extensive knowledge in orthopaedics which is a prerequisite for our increased focus on this segment in the future.”

Dr. Thomas will lead the medical affairs, clinical research, regulatory affairs and quality systems departments and is now part of curasan’s senior management team.

About curasan AG:

curasan AG develops manufactures and markets biomaterials and other medical products in the field of bone and tissue regeneration. A pioneer in its industry, curasan is specialized primarily on synthetic bone grafting ¬materials for dental and orthopedic applications. Numerous patents and a comprehensive list of scientific documentation prove the clinical success of the products and the highly innovative strength of curasan. Surgically active dentists, implantologists and oral, maxillary and dentofacial surgeons, as well as orthopedics, traumatologists and spinal column surgeons worldwide benefit from the broad range of the premium quality and user-oriented portfolio offered by the technology leader. curasan maintains its own high-tech facilities for research, development and manufacturing in Frankfurt/Main, Germany, which are approved by the Food and Drug Administration (FDA) and other international authorities. In addition to its headquarters, the company has a subsidiary, curasan Inc., located in North Carolina, USA. The shares of curasan AG are listed in the General Standard at the Frankfurt Stock Exchange.

Josh Sandberg

Josh Sandberg is the President and CEO of Ortho Spine Partners and sits on several company and industry related Boards. He also is the Creator and Editor of OrthoSpineNews.

Related Articles

Back to top button